New data from EMPEROR-Preserved: patient population, efficacy endpoints and safety of empagliflozin in patients with and without diabetes
In this medfyle
Expert commentary by Prof. Zelija Velija Asimi
This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.
Acknowledgements
This is a highlights summary of an oral session given at the Virtual EASD Annual Meeting 2021 and presented by:
Prof. Gerasimos Filippatos
National and Kapodistrian University of Athens, Attikon University Hospital
Athens, Greece
The content is produced by Infomedica. The presenting authors of the original session had no part in the creation of this conference highlights summary.
In addition, an expert commentary on the topic has been provided by:
Prof. Zelija Velija Asimi, MD, PhD, FACE
President of Society of Endocrinology and Diabetology in Bosnia and Herzegovina
Professor of Internal Medicine and, Endocrinology and Diabetology, Sarajevo Medical School, SSST University
About the Expert
Prof. Zelija Velija Asimi, MD, PhD, FACE
President of Society of Endocrinology and Diabetology in Bosnia and Herzegovina
Professor of Internal Medicine and, Endocrinology and Diabetology, Sarajevo Medical School, SSST University
Prof. Zelia Velija Asimi is a Specialist of Internal Medicine and a Subspecialist of Endocrinology and Diabetology, and a Fellow of the American College of Endocrinology (FACE).
She is the president of the Society of Endocrinologists and Diabetologists in Bosnia and Herzegovina since 2016, and a member of the Membership Committee of the European Society of Endocrinology (2020-2024).
Zelija Velija Asimi was Associate Professor from 2013 to 2019, at the Department of Internal Medicine - subject of Endocrinology and Diabetology, at the Medical Faculty of the University of Sarajevo, and now she is a full professor of Internal Medicine and Endocrinology and Diabetology at Sarajevo Medical School, SSST University. For many years she worked at the Clinical Centre of the Sarajevo University as the head of the diagnostic and polyclinic department of the Clinic for Endocrinology and Diabetology. She now works as a consultant in Endocrinology and Diabetology at the private outpatient clinic in Sarajevo.
Professor Velija Asimi is the author of many peer-reviewed books, university textbooks, peer-reviewed guides, and many scientific and professional papers. She has participated in many scientific projects, and she completed continuing professional education in health management.
References
1. Anker SD, Butler J, Filippatos G, et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med. 2021 Aug 27. doi: 10.1056/NEJMoa2107038.
